Sanofi to overhaul US operations of vaccines, cut jobs
Reuters
Published Apr 18, 2024 04:28PM ET
Updated Apr 18, 2024 04:43PM ET
(Reuters) - French drugmaker Sanofi (NASDAQ:SNY) said on Thursday it would restructure the U.S. commercial operations for its vaccines and cut an undisclosed number of jobs.
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted.
Endpoints News first reported the development on Thursday.
Sanofi CEO Paul Hudson (NYSE:HUD) has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending.
The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.